MINIMS PHOSPHATE SODIQUE DE PREDNISOLONE Gouttes

国: カナダ

言語: フランス語

ソース: Health Canada

有効成分:

Phosphate sodique de prednisolone

から入手可能:

BAUSCH & LOMB INC

ATCコード:

S01BA04

INN（国際名）:

PREDNISOLONE

投薬量:

0.5%

医薬品形態:

Gouttes

構図:

Phosphate sodique de prednisolone 0.5%

投与経路:

Ophtalmique

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

CORTICOSTEROIDS

製品概要:

Numéro de groupe d'ingrédients actifs (GIA) :0106288003; AHFS:

認証ステータス:

APPROUVÉ

承認日:

2020-12-01

製品の特徴

_ _
ENGLISH
FRENCH
PR
MINIMS
® PREDNISOLONE SODIUM
PHOSPHATE
Prednisolone Sodium Phosphate Ophthalmic Solution,
USP
CORTICOSTEROID
PRESCRIBING INFORMATION
PRESENTATION
Single dose clear, colorless, sterile eye drops, available as
0.5% w/v solution. Contains no preservative.
ACTION
MINIMS PREDNISOLONE SODIUM
PHOSPHATE exerts its effect on the anterior segment of
the eye by inhibition of inflammatory response to inciting
agents of mechanical, chemical or immunological nature.
INDICATIONS
Single use of MINIMS PREDNISOLONE SODIUM
PHOSPHATE is indicated in the following noninfectious
inflammatory allergic conditions: allergic, non-purulent
catarrhal, and vernal conjunctivitis; acute iritis; catarrhal
corneal ulcer, cornea injuries; non-purulent blepharitis;
nonspecific superficial keratitis; non-purulent phlyctenular
kerato-conjunctivitis. During the course of therapy, if the
inflammatory reaction does not respond within a
reasonable period, institute other forms of therapy.
CONTRANDICATIONS
•
Viral disease of the cornea and conjunctiva;
tuberculosis of the eye; fungal disease of the eye;
acute purulent untreated infections of the eye,
which like other diseases caused by micro-
organisms, may be masked or enhanced by the
presence of the steroid.
•
Herpes simplex, varicella and vaccinia.
•
Hypersensitivity to any of the components of the
medication.
WARNINGS
The use of corticosteroid ophthalmic drops during
pregnancy or in infants should be avoided.
PRECAUTIONS
Fungal infection must be suspected in any persistent
corneal ulceration where a steroid has been used or is in
use. Increased intraocular pressure may develop following
extended ophthalmic use of corticosteroid. Since increased
intraocular pressure can lead to loss of vision, ophthalmic
administration should be used only under adequate
tonometric supervision in patients known to have
glaucoma or have family history of glaucoma.
As with adrenal corticosteroids, prednisolone sodium
phosphate may mask, activate or enhance infection. If
there is a possibility